Dergiler / Uluslararası Hematoloji-Onkoloji Dergisi / 2019 / Cilt: 29 - Sayı: 1

The Pain Relief and Recalcification Results of Radiotherapy for Plasma Cell Tumors

Plasma Hücreli Tümörlerde Radyoterapinin Ağrı Kesici ve Rekalsifikasyon Etkisi

Sayfa
1–6
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

It can be stated that treatment doses over 30 Gy with multiple fractions should be suggested for the patients in good general condition with a life expectancy of > 1year.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Multiple Myeloma (MM) and Solitary Plasmocytoma (SP) are given as Plasma Cell Neoplasms (PCNs).
📊
Temel Bulgular & Veri:From January 2009 to December 2016, total 80 patients were evaluated.
💡
Sonuç & Katkı:It can be stated that treatment doses over 30 Gy with multiple fractions should be suggested for the patients in good general condition with a life expectancy of > 1year.
🔬Tür:Araştırma Makalesi
📍Kapsam:2009 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Multiple Myeloma (MM) and Solitary Plasmocytoma (SP) are given as Plasma Cell Neoplasms (PCNs). Radiotherapy (RT) is used for definitive and/or palliative purposes.We aimed to evaluate the role of RT upon pain relief,recalcification and local disease control for the patients with PCNs. From January 2009 to December 2016, total 80 patients were evaluated. Eleven (13.8%) patients were classified as SP, and 69 (86.3%) were as MM. The total treatment dose was 45 Gy with 1.8 Gy per fraction for the SP and total 30 Gy with 2.5- 3 Gy per fraction for the MM. Numerical Rating Pain Scale (NRS) was used for pain level detection and the international consensus on palliative RT criteria was used for recalcification level classification before and after RT. Prior to RT, 56 (70%) patients suffered from severe pain, 19 (23.8%) patients suffered from moderate pain and only 5 (6.3%) patients reported mild pain. After RT, complete pain relief was achieved in 59 (73.8%) and partial pain relief was reported remaining 14 (17.5%) patients. We identified some kind of radiologic recalcification response in 77 (96.3%) patients. Complete and partial radiological response was recorded in 41 (51.3%) and 36 (45%) patients, respectively. Complete recalcification response was seen in 9 of 11 (82%) SP patients and 32 of 69 (46%) MM patients. The difference of complete recalcification response rates between two groups was significant (p= 0.031).Local disease control was achieved in 75 (94%) patients. The time interval after RT and applied RT doses are important factors for recalcification effect. Unlikely, pain relief can be achieved regardless of dose level. It can be stated that treatment doses over 30 Gy with multiple fractions should be suggested for the patients in good general condition with a life expectancy of > 1year.

Abstract

Multipl myelom (MM) ve Soliter Plazmositom (SP), Plasma Hücreli Tümörlerdir (PHT). Radyoerapi (RT) PHT’lerde definitif ve/veya palyatif amaçla tedavinin bir parçası olarak kullanılır. PHT’lerde RT’nin ağrı kesici, rekalsifikasyon ve lokal hastalık konrol etkisini araştırmayı amaçladık. Ocak 2009-Aralık 2016 tarihleri arasında, 11 (14%) SP ve 69 (%86) MM tanılı toplam 80 hastayı değerlendirdik. Toplam tedavi dozu, SP için 1.8 Gy fraksiyon dozu ile 45 Gy, MM için 2.5 Gy fraksiyon dozu ile 30 Gy’dir. Tedavi öncesi ve sonrası olmak üzere, ağri seviyesi için Numerical Rating Pain Scale (NRS) ve rekalsifikasyon için uluslararası konsensus kriterleri kullanılmıştır. RT öncesi, ciddi, orta ve ılımlı ağrı mevcut olan hasta sayısı sırasıyla 56(%70), 19 (%24) ve 5 (%6)’dır. RT sonrası, tam ve kısmi ağrı azalması yanıtı sırasıyla 59 (%74) ve 14 (%18) hastada elde edilmiştir. Herhangi bir radyolojik yanıt 77 (%96) hastada elde edilmiştir. Tam ve kısmi radyolojik yanıt oranları sırasıyla 41 (%51) ve 36 (%45) hastada izlenmiştir. Tam rekalsifikasyon yanıtı 11 SP’un 9 (%82)’unda, 69 MM’un 32 (%46)’sinde elde edilmiştir. Bu farklılık istatistiksel olarak anlamlıdır (p= 0.031). Lokal hastalık kontrolü 75 (%94) hastada elde edilmiştir. RT sonrası geçen zaman ve uygulanan RT dozu, rekalsifikasyon için önemli faktörlerdir. Farklı olarak, ağrı kesici etkisi uygulanan RT dozundan bağımsızdı. Yaşam beklentisi > 1yıl olan genel durumu iyi hastalara çoklu fraksiyonlarla 30 Gy’in üzerinde tedavi dozları önerilebilir.

🔖

Bu Makaleye Atıf Yap

SERT, F., KAMER, S., SAYDAM, G., ANACAK, Y. (2019). The Pain Relief and Recalcification Results of Radiotherapy for Plasma Cell Tumors. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 29 - Sayı: 1, 1–6. https://ajindex.com/articles/323293

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Dores GM, Landgren O, McGlynn KA, et al. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol 144: 86-94, 2009
  2. Balducci M, Chiesa S, Manfrida S, et al. Impact of radiotherapy on pain relief and recalcification in plasma cell neoplasms: long-term experience. Strahlenther Onkol 187: 114-119, 2011
  3. Stölting T, Knauerhase H, Klautke G, et al. Total and single doses influence the effectiveness of radiotherapy in palliative treatment of plasmacytoma. Strahlenther Onkol 184: 465- 472, 2008
  4. Dimopoulos MA, Goldstein J, Fuller L, et al. Curability of solitary bone plasmacytoma. J Clin Oncol 10: 587-590, 1992
  5. Farhangi M, Ossermann E. The treatment of multiple myeloma. Semin Hematol 10: 149-161, 1973
  6. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121: 749-757, 2003
  7. Wambersie A, Menzel HG, Andreo P, et al. Isoeffective dose: a concept for biological weighting of absorbed dose in proton and heavier-ion therapies. Radiat Prot Dosimetry 143: 481- 486, 2011
  8. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23: 129-138, 1994
  9. Chow E, Doyle M, Li K, et al. Mild, moderate, or severe pain categorized by patients with cancer with bone metastases. J Palliat Med 9: 850-854, 2006
  10. Chow E, Wu JS, Hoskin P, et al. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 64: 275-280, 2002
  11. Vassiliou V, Tselis N, Kardamakis D. Osteonecrosis of the jaws: clinicopathologic and radiologic characteristics, preventive and therapeutic strategies. Strahlenther Onkol 186: 367-373, 2010
  12. Vakaet LA, Boterberg T. Pain control by ionizing radiation of bone metastasis. Int J Dev Biol 48: 599-606, 2004
  13. Halperin EC, Wazer DE, Perez CA, Brandy LW. Principles and Practice of Radiation Oncology. 6th edition. Philadelphia, Lippincott Williams and Wilkins, 2013: 130-203
  14. Rudzianskiene M, Inciura A, Gerbutavicius R, et al. Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma: A prospective randomised study. Strahlenther Onkol 193: 742-749, 2017. 15. van der Linden YM, Lok JJ, Steenland E, et al; Dutch Bone Metastasis Study Group. Single fraction radi